Shuangshuang Fu1, Michael Wang2, Ruosha Li3, David R Lairson4, Bo Zhao3, Xianglin L Du5. 1. Department of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: miwang@mdanderson.org. 3. Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. 4. Department of Management Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. 5. Department of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Electronic address: Xianglin.L.Du@uth.tmc.edu.
Abstract
BACKGROUND: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. METHODS: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995-1998, P1), rituximab + chemotherapy (1999-2004, P2), bortezomib and HyperCVAD (2005-2008, P3), bendamustine and Nordic regimen (2009-2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions. RESULTS: A total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets. CONCLUSION: Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.
BACKGROUND: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. METHODS: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995-1998, P1), rituximab + chemotherapy (1999-2004, P2), bortezomib and HyperCVAD (2005-2008, P3), bendamustine and Nordic regimen (2009-2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions. RESULTS: A total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets. CONCLUSION: Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.
Authors: Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen Journal: Br J Haematol Date: 2012-05-29 Impact factor: 6.998
Authors: Anna Abrahamsson; Alexandra Albertsson-Lindblad; Peter N Brown; Stefanie Baumgartner-Wennerholm; Lars M Pedersen; Francesco D'Amore; Herman Nilsson-Ehle; Paw Jensen; Michael Pedersen; Christian H Geisler; Mats Jerkeman Journal: Blood Date: 2014-05-23 Impact factor: 22.113
Authors: Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger Journal: Lancet Date: 2013-02-20 Impact factor: 79.321
Authors: Annina Herrmann; Eva Hoster; Thomas Zwingers; Günter Brittinger; Marianne Engelhard; Peter Meusers; Marcel Reiser; Roswitha Forstpointner; Bernd Metzner; Norma Peter; Bernhard Wörmann; Lorenz Trümper; Michael Pfreundschuh; Hermann Einsele; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Yuhong Zhou; Haijun Wang; Wenjing Fang; Jorge E Romaguer; Yanxia Zhang; Kay B Delasalle; Larry Kwak; Qing Yi; Xianglin L Du; Michael Wang Journal: Cancer Date: 2008-08-15 Impact factor: 6.860
Authors: Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke Journal: Blood Date: 2014-03-03 Impact factor: 22.113
Authors: Mengyang Di; Can Cui; Shalin K Kothari; Amer M Zeidan; Nikolai A Podoltsev; Natalia Neparidze; Rory M Shallis; Rong Wang; Xiaomei Ma; Scott F Huntington Journal: Blood Adv Date: 2022-06-14